S. Hariharan

HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study.

L. Chow, R. Cohen, D. Gustafson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state

L. Chow, S. Leong, R. Boinpally, 2009, Cancer Chemotherapy and Pharmacology.

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.

M. von Mehren, D. Camidge, L. Chow, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pre-clinical toxicity & immunobiological evaluation of DNA rabies vaccine & combination rabies vaccine in rhesus monkeys (Macaca mulatta)

P. Rangarajan, T. P. Krishna, K. Krishnaswamy, 2013, The Indian journal of medical research.

Assessment of the biological and pharmacological effects of the a n b 3 and a n b 5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors

S. Eckhardt, D. Gallemann, M. Morrow, 2007 .

Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors

Daniel L. Gustafson, Anna E. Barón, A. Baron, 2007 .

Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.

A. Baron, D. McConkey, D. Gustafson, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Nonclinical toxicology study of recombinant-plasmid DNA anti-rabies vaccines.

P. Rangarajan, T. P. Krishna, K. Krishnaswamy, 2006, Vaccine.

26 ORAL Phase Ib and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid malignancies

W. Franklin, A. Adjei, R. Cohen, 2006 .